Qiagen (QGEN) Reports Q2 Earnings: What Key Metrics Have to Say

Qiagen (QGEN) reported Q2 2025 revenue of $533.54 million, a 7.5% year-over-year increase, surpassing the Zacks Consensus Estimate of $524.1 million by 1.8%, while EPS of $0.60 met expectations. Segment performance was mixed, with strong growth in QIAstat-Dx sales (+41.7% YoY) and 'Other' product groups (+57.1% YoY) beating estimates, yet NeuMoDx sales declined significantly by 57.1% and Genomics/NGS slightly missed projections. QGEN shares have outperformed the S&P 500 over the past month, returning +5.7% versus +1%, and the stock holds a Zacks Rank #2 (Buy), indicating potential near-term outperformance.

Analysis

Qiagen (QGEN) delivered a mixed but overall positive Q2 2025 earnings report, characterized by a top-line beat and specific areas of significant operational strength. Revenue grew 7.5% year-over-year to $533.54 million, surpassing the consensus estimate by 1.8%, while earnings per share of $0.60 met analyst expectations precisely. A deeper look at the product segments reveals a divergent performance profile. The Diagnostic Solutions group was a key driver, with sales up 11.4% YoY, led by exceptional growth in QIAstat-Dx, which surged 41.7% YoY to $34 million, and solid performance from the core QuantiFERON platform, which grew 12.2% to $129 million. However, this strength was partially offset by a significant contraction in the NeuMoDx platform, where sales plummeted 57.1% YoY to just $3 million, substantially missing estimates. Furthermore, other core segments showed minimal expansion, with Genomics/NGS growing only 1.7% and Sample Technologies up just 1.2%, indicating concentrated growth drivers rather than broad-based acceleration. The stock's recent 5.7% gain over the past month, outperforming the S&P 500, suggests the market is focusing on the positive revenue surprise and key growth areas, a sentiment reinforced by its current Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should analyze the quality of the revenue growth, focusing on whether continued strength in the QIAstat-Dx and QuantiFERON platforms can sustainably offset the material 57.1% decline in NeuMoDx sales.
• Monitor subsequent quarters for signs of stabilization or recovery in the underperforming Genomics/NGS and Sample Technologies segments, as their near-flat growth could become a drag on overall performance.
• Given the stock's recent outperformance and the in-line EPS result, consider whether the positive segment news is already reflected in the current valuation, despite the bullish near-term analyst rating.